Eosinophilic Esophagitis Disease Treatment Market - Forecasts from 2025 to 2030

The eosinophilic esophagitis disease treatment market is projected to grow at a CAGR of 8.15% over the forecast period, increasing from US$504.625 million in 2025 to US$745.096 million by 2030.

Eosinophilic esophagitis (EoE) is a type of allergic inflammatory disease that involves a white blood cell type, eosinophils. Its major symptoms include heartburn, chest pain, and difficulty in swallowing. There are no major medicines that can cure EOE, and multiple foods like shellfish, fish sauce, and oyster sauce can cause it.

The global increase in asthma and allergy cases is estimated to push the global eosinophilic esophagitis disease treatment market forward. The patients suffering from EOE majorly have other conditions like allergic rhinitis, food allergies, or asthma. The Asthma and Allergy Foundation of America, in its report, stated that about 76% of EOE patients have food allergy as a comorbid condition, 70% have Allergic rhinitis, and 51% have asthma. The comorbid condition prevalence of atopic dermatitis and irritable bowel syndrome are 41% and 16%, respectively.

Eosinophilic Esophagitis Disease Treatment Market Geographical Outlook:

The North American region is expected to propel with the highest CAGR in the projected period.

The rising prevalence of this disease in the United States is one of the major reasons for the increased demand for EoE treatment in the coming years. For instance, the National Organization for Rare Disorders, Inc. (NORD) which published an article in March 2024, on Eosinophilic Esophagitis, stated that standardized to the U.S. population it has been estimated that 56.7 per 100,000 people in the US are suffering from eosinophilic esophagitis disease, which makes a total of 152,152 cases in total. Additionally, in the past two decades in the U.S., the cases of EoE have almost doubled in both adults and children. Hence, such stats are anticipated to fuel the eosinophilic esophagitis disease treatment market in the coming years.

The rising drug approval for the treatment of this disease of also expected to have a positive impact on the market growth in the coming years. For instance, in January 2024, the Food and Drug Administration (FDA) in the United States approved Dupixent® (dupilumab) for treating EoE for children aged 1 year or older. This approval extends the initial FDA approval for EOE in May 2022 for patients aged 12 years and older and weighing 40 kg. The FDA evaluated Dupixent for this expanded indication under priority review, and this drug proved to have efficiently and safely treated this rare condition. Hence, these product launches are one of the main reasons for market growth in the projected period.

Additionally, the rising healthcare expenditure in the country is anticipated to fuel the market growth in the forecasted period. For instance, according to the U.S. Centers for Medicare & Medicaid Services, and American Medical Services, the per capita healthcare expenditure in 2021 was US$12,914 or US$4.3 billion in total spend in healthcare. This number increased to US$4.5 billion in total healthcare spending, and per capita spending of US$13,493 in 2022. Hence, in the projected period, rising per capita healthcare spending is also expected to positively impact the eosinophilic esophagitis disease treatment market growth.

Reasons for buying this report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Eosinophilic Esophagitis Disease Treatment market is analyzed into the following segments:

By Product Type

• Off-Label Drugs
• Budesonide Oral Suspension
• Fluticasone ODT
• Mepolizumab
• Reslizumab
• Benralizumab
• Dupilunab
• Omalizumab

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• South America
• Europe
• Middle East and Africa
• Asia-Pacific